URSULA CARLISLE: Open Payments
NPI 1770083909 · BOSSIER CITY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,821 in 129 payments from 33 companies in 2025. Trend: 2023 $1,340 · 2024 $2,624 · 2025 $2,821
Food & beverage: $2,821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $293 |
| AstraZeneca Pharmaceuticals LP | 8 | $248 |
| GlaxoSmithKline, LLC. | 8 | $174 |
| Sumitomo Pharma America, Inc. | 7 | $156 |
| Astellas Pharma US Inc | 9 | $140 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $138 |
| Alkermes, Inc. | 10 | $137 |
| Melinta Therapeutics, LLC | 1 | $125 |
| KYOWA KIRIN, INC. | 1 | $125 |
| Sage Therapeutics, LLC | 1 | $120 |
Products named: AIRSUPRA, VRAYLAR, TRELEGY ELLIPTA, GEMTESA, Veozah, Kerendia, Rezzayo, ARISTADA.
Industry payments across LA — which companies pay providers there.
